RIDGEFIELD, Conn., May 28, 2014 /PRNewswire/ -- Boehringer Ingelheim (BI) announced today that it has reached a comprehensive settlement of state and federal cases in the U.S. litigation regarding ...
RIDGEFIELD, Conn., May 4, 2018 /PRNewswire/ -- Today, Boehringer Ingelheim announced that Praxbind® (idarucizumab), a specific reversal agent for Pradaxa® (dabigatran etexilate mesylate), is now ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results